Recent Macrolide Resistance Pattern of Mycoplasma Pneumonia in the World: A Systematic Review and Meta-Analysis
,
1. Carrie R, Chris S, Evan J, et al (2015). Community-acquired pneumonia requiring hospitalization among US children. N Engl J Med, 372 (9):835-45.
2. Shin EJ, Kim Y, Jeong JY, et al (2018). The changes of prevalence and etiology of pediatric pneumonia from National Emergency Department Information System in Korea, between 2007 and 2014. Korean J Pediatr, 61 (9):291-300.
3. Waites KB, Talkington DF (2004). Mycoplasma pneumoniae and its role as a human pathogen. Clin Microbiol Rev, 17 (4):697-728.
4. Narita M (2010). Pathogenesis of extrapulmonary manifestations of Mycoplasma pneumoniae infection with special reference to pneumonia. J Infect Chemother, 16 (3):162-9.
5. Principi N, Esposito S (2013). Macrolide-resistant Mycoplasma pneumoniae: its role in respiratory infection. J Antimicrob Chemother, 68 (3):506-11.
6. de Groot RCA, Meyer Sauteur PM, Unger WWJ, et al (2017). Things that could be Mycoplasma pneumoniae. J Infect, 74 Suppl 1:S95-S100.
7. Pereyre S, Goret J, Bébéar C (2016). Mycoplasma pneumoniae: Current Knowledge on Macrolide Resistance and Treatment. Front Microbiol, 7:974.
8. Dumke R, Catrein I, Herrmann R, Jacobs E (2004). Preference, adaptation and survival of Mycoplasma pneumoniae subtypes in an animal model. Int J Med Microbiol, 294 (2-3):149-55.
9. Atkinson TP, Balish MF, Waites KB (2008). Epidemiology, clinical manifestations, pathogenesis and laboratory detection of Mycoplasma pneumoniae infections. FEMS Microbiol Rev, 32 (6):956-73.
10. Rasmussen JN, Voldstedlund M, Andersen RL, et al (2010). Increased incidence of Mycoplasma pneumoniae infections detected by laboratory-based surveillance in Denmark in 2010. Euro Surveill, 15 (45): 19708.
11. Gullsby K, Olsen B, Bondeson K (2019). Molecular Typing of Mycoplasma pneumoniae Strains in Sweden from 1996 to 2017 and the Emergence of a New P1 Cytadhesin Gene, Variant 2e. J Clin Microbiol, 57 (6):e00049-19.
12. Morozumi M, Takahashi T, Ubukata K (2010). Macrolide-resistant Mycoplasma pneumoniae: characteristics of isolates and clinical aspects of community-acquired pneumonia. J Infect Chemother, 16 (2):78-86.
13. Chironna M, Sallustio A, Esposito S, et al (2011). Emergence of macrolide-resistant strains during an outbreak of Mycoplasma pneumoniae infections in children. J Antimicrob Chemother, 66 (4):734-737.
14. Okazaki N, Narita M, Yamada S, et al (2001). Characteristics of macrolide-resistant Mycoplasma pneumoniae strains isolated from patients and induced with erythromycin in vitro. Microbiol Immunol, 45 (8):617-20.
15. Hubert D, Dumke R, Weichert S, et al (2021). Emergence of Macrolide-Resistant Mycoplasma pneumoniae during an Outbreak in a Primary School: Clinical Characterization of Hospitalized Children. Pathogens, 10 (3):328.
16. Miyashita N, Akaike H, Teranishi H, et al (2013). Macrolide-Resistant Mycoplasma pneumoniae Pneumonia in Adolescents and Adults: Clinical Findings, Drug Susceptibility, and Therapeutic Efficacy. Antimicrob Agents Chemother, 57 (10):5181-5185.
17. Moher D, Liberati A, Tetzlaff J, et al (2009). Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med, 151 (4):264-9, W64.
18. Wang Y, Xu B, Wu X, et al (2021). Increased Macrolide Resistance Rate of M3562 Mycoplasma pneumoniae Correlated With Macrolide Usage and Genotype Shifting. Front Cell Infect Microbiol, 11:675466.
19. Sun H, Xue G, Yan C, et al (2017). Changes in Molecular Characteristics of Mycoplasma pneumoniae in Clinical Specimens from Children in Beijing between 2003 and 2015. PLoS One, 12 (1):e0170253.
20. Yan C, Xue G, Zhao H, et al (2019). Molecular and clinical characteristics of severe Mycoplasma pneumoniae pneumonia in children. Pediatr Pulmonol, 54 (7):1012-1021.
21. Nakamura Y, Oishi T, Kaneko K, et al (2021). Recent acute reduction in macrolide-resistant Mycoplasma pneumoniae infections among Japanese children. J Infect Chemother, 27 (2):271-276.
22. Okada T, Morozumi M, Tajima T, et al (2012). Rapid effectiveness of minocycline or doxycycline against macrolide-resistant Mycoplasma pneumoniae infection in a 2011 outbreak among Japanese children. Clin Infect Dis, 55 (12):1642-9.
23. Morozumi M, Tajima T, Sakuma M, et al (2020). Sequence Type Changes Associated with Decreasing Macrolide-Resistant Mycoplasma pneumoniae, Japan. Emerg Infect Dis, 26 (9):2210-2213.
24. Xue G, Li M, Wang N, et al (2018). Comparison of the molecular characteristics of Mycoplasma pneumoniae from children across different regions of China. PLoS One, 13 (8):e0198557.
25. Zhao F, Li J, Liu J, et al (2019). Antimicrobial susceptibility and molecular characteristics of Mycoplasma pneumoniae isolates across different regions of China. Antimicrob Resist Infect Control, 8:143.
26. Lenglet A, Herrador Z, Magiorakos AP, et al (2012). Surveillance status and recent data for Mycoplasma pneumoniae infections in the European Union and European Economic Area, January 2012. Euro Surveill, 17 (5): 20075.
27. Adriaenssens N, Coenen S, Versporten A, et al (2011). European Surveillance of Antimicrobial Consumption (ESAC): outpatient macrolide, lincosamide and streptogramin (MLS) use in Europe (1997-2009). J Antimicrob Chemother, 66 Suppl 6:vi37-45.
28. Dumke R, Ziegler T (2019). Long-Term Low Rate of Macrolide-Resistant Mycoplasma pneumoniae Strains in Germany. Antimicrob Agents Chemother, 63 (5):e00455-19.
29. Ferguson GD, Gadsby NJ, Henderson SS, et al (2013). Clinical outcomes and macrolide resistance in Mycoplasma pneumoniae infection in Scotland, UK. J Med Microbiol, 62 (Pt 12):1876-1882.
30. Kurkela S, Puolakkainen M, Hokynar K, et al (2019). Mycoplasma pneumoniae outbreak, Southeastern Finland, 2017–2018: molecular epidemiology and laboratory diagnostic lessons. Eur J Clin Microbiol Infect Dis, 38 (10):1867-1871.71.
31. Pereyre S, Guyot C, Renaudin H, et al (2004). In vitro selection and characterization of resistance to macrolides and related antibiotics in Mycoplasma pneumoniae. Antimicrob Agents Chemother, 48 (2):460-5.
32. Waites KB, Balish MF, Atkinson TP (2008). New insights into the pathogenesis and detection of Mycoplasma pneumoniae infections. Future Microbiol, 3 (6):635-48.
33. Morozumi M, Hasegawa K, Kobayashi R, et al (2005). Emergence of macrolide-resistant Mycoplasma pneumoniae with a 23S rRNA gene mutation. Antimicrob Agents Chemother, 49 (6):2302-6.
34. Cao B, Zhao CJ, Yin YD, et al (2010). High prevalence of macrolide resistance in Mycoplasma pneumoniae isolates from adult and adolescent patients with respiratory tract infection in China. Clin Infect Dis, 51 (2):189-94.
35. Zhao F, Liu G, Wu J, et al (2013). Surveillance of Macrolide-Resistant Mycoplasma pneumoniae in Beijing, China, from 2008 to 2012. Antimicrob Agents Chemother, 57 (3):1521-1523.
36. Zhao F, Liu L, Tao X, et al (2015). Culture-Independent Detection and Genotyping of Mycoplasma pneumoniae in Clinical Specimens from Beijing, China. PLoS One, 10 (10):e0141702.
37. Zhao H, Li S, Cao L, et al (2014). Surveillance of Mycoplasma pneumoniae infection among children in Beijing from 2007 to 2012. Chin Med J (Engl), 127 (7):1244-8.
38. Zhou Y, Zhang Y, Sheng Y, et al (2014). More Complications Occur in Macrolide-Resistant than in Macrolide-Sensitive Mycoplasma pneumoniae Pneumonia. Antimicrob Agents Chemother, 58 (2):1034-1038.
39. Oishi T, Takahashi K, Wakabayashi S, et al (2019). Comparing Antimicrobial Susceptibilities among Mycoplasma pneumoniae Isolates from Pediatric Patients in Japan between Two Recent Epidemic Periods. Antimicrob Agents Chemother, 63 (7):e02517-18.
40. Yu JL, Song QF, Xie ZW, et al (2017). iTRAQ-based Quantitative Proteomics Study in Patients with Refractory Mycoplasma pneumoniae Pneumonia. Jpn J Infect Dis, 70 (5):571-578.
41. Cardinale F, Chironna M, Chinellato I, et al (2013). Clinical Relevance of Mycoplasma pneumoniae Macrolide Resistance in Children. J Clin Microbiol, 51 (2):723-724.
42. Spuesens EB, Meyer Sauteur PM, Vink C, et al (2014). Mycoplasma pneumoniae infections--does treatment help? J Infect, 69 Suppl 1:S42-6.
43. Luo Z, Luo J, Liu E, et al (2014). Effects of prednisolone on refractory mycoplasma pneumoniae pneumonia in children. Pediatr Pulmonol, 49 (4):377-80.
44. Oliva A, Siccardi G, Migliarini A, et al (2020). Co-infection of SARS-CoV-2 with Chlamydia or Mycoplasma pneumoniae: a case series and review of the literature. Infection, 48 (6):871-877.
45. Rothstein TE, Cunningham SA, Rieke RA, et al (2022). Macrolide Resistance in Mycoplasma pneumoniae, Midwestern United States, 2014 to 2021. Antimicrob Agents Chemother, 66 (4):e0243221.
46. Guo Z, Liu L, Gong J, et al (2022). Molecular features and antimicrobial susceptibility of Mycoplasma pneumoniae isolates from paediatric inpatients in Weihai, China: Characteristics of M. pneumoniae In Weihai. J Glob Antimicrob Resist, 28:180-184.
47. Chen D, Zhang NL, Zhang T, et al (2021). [Detection of drug-resistance genes of Mycoplasma pneumoniae in bronchoalveolar lavage fluid of children with refractory Mycoplasma pneumoniae pneumonia]. Zhongguo Dang Dai Er Ke Za Zhi, 23(7):707-712.
48. Kakiuchi T, Miyata I, Kimura R, et al (2021). Clinical Evaluation of a Novel Point-of-Care Assay To Detect Mycoplasma pneumoniae and Associated Macrolide-Resistant Mutations. J Clin Microbiol, 59 (7):e0324520.
49. Kuo CY, Tsai WC, Lee HF, et al (2022). The epidemiology, clinical characteristics, and macrolide susceptibility of Mycoplasma pneumoniae pneumonia in children in Southern Taiwan, 2019-2020. J Microbiol Immunol Infect, 55(4):611-619.
50. Dou HW, Tian XJ, Xin L, et al (2020). Mycoplasma pneumoniae Macrolide Resistance and MLVA Typing in Children in Beijing, China, in 2016: Is It Relevant? Biomed Environ Sci, 33 (12):916-924.
51. Morinaga Y, Suzuki H, Notake S, et al (2020). Evaluation of GENECUBE Mycoplasma for the detection of macrolide-resistant Mycoplasma pneumoniae. J Med Microbiol, 69 (12):1346-1350.
52. Rivaya B, Jordana-Lluch E, Fernández-Rivas G, et al (2020). Macrolide resistance and molecular typing of Mycoplasma pneumoniae infections during a 4 year period in Spain. J Antimicrob Chemother, 75 (10):2752-2759.
53. Hung HM, Chuang CH, Chen YY, et al (2021). Clonal spread of macrolide-resistant Mycoplasma pneumoniae sequence type-3 and type-17 with recombination on non-P1 adhesin among children in Taiwan. Clin Microbiol Infect, 27 (8):1169.e1-1169.e6.
54. Noori Goodarzi N, Pourmand MR, Arfaatabar M, et al (2020). First Detection and Characterization of Macrolide-Resistant Mycoplasma pneumoniae from People with Community-Acquired Pneumonia in Iran. Microb Drug Resist, 26 (3):245-250.
55. Waites KB, Ratliff A, Crabb DM, et al (2019). Macrolide-Resistant Mycoplasma pneumoniae in the United States as Determined from a National Surveillance Program. J Clin Microbiol, 57 (11): e00968-19.
56. Guo D, Hu W, Xu B, et al (2019). Allele-specific real-time PCR testing for minor macrolide-resistant Mycoplasma Pneumoniae. BMC Infect Dis, 19 (1):616.
57. Yang TI, Chang TH, Lu CY, et al (2019). Mycoplasma pneumoniae in pediatric patients: Do macrolide-resistance and/or delayed treatment matter? J Microbiol Immunol Infect, 52 (2):329-335.
58. Lu CY, Yen TY, Chang LY, et al (2020). Multiple-locus variable-number tandem-repeat analysis (MLVA) of macrolide-susceptible and -resistant Mycoplasma pneumoniae in children in Taiwan. J Formos Med Assoc, 119 (10):1539-1545.
59. Rodriguez N, Mondeja B, Sardiñas R, et al (2019). First detection and characterization of macrolide-resistant Mycoplasma pneumoniae strains in Cuba. Int J Infect Dis, 80:115-117.
60. Zhao F, Liu J, Shi W, et al (2019). Antimicrobial susceptibility and genotyping of Mycoplasma pneumoniae isolates in Beijing, China, from 2014 to 2016. Antimicrob Resist Infect Control, 8:18.
61. Loconsole D, De Robertis AL, Mallamaci R, et al (2019). First Description of Macrolide-Resistant Mycoplasma pneumoniae in Adults with Community-Acquired Pneumonia in Italy. Biomed Res Int, 2019:7168949.
62. Katsukawa C, Kenri T, Shibayama K, et al (2019). Genetic characterization of Mycoplasma pneumoniae isolated in Osaka between 2011 and 2017: Decreased detection rate of macrolide-resistance and increase of p1 gene type 2 lineage strains. PLoS One, 14 (1):e0209938.
63. Guo DX, Hu WJ, Wei R, et al (2019). Epidemiology and mechanism of drug resistance of Mycoplasma pneumoniae in Beijing, China: A multicenter study. Bosn J Basic Med Sci, 19 (3):288-296.
64. Choi JH, Seong GM, Ko Y, et al (2019). Prevalence and Clinical Features of Community-Acquired Pneumonia Caused by Macrolide-Resistant Mycoplasma pneumoniae Isolated from Adults in Jeju Island. Microb Drug Resist, 25 (4):577-581.
65. Shinto K, Kato K, Narita T, et al (2018). [Evaluation of novel nucleic acid detection kit for Mycoplasma pneumoniae]. Rinsho Biseibutshu Jinsoku Shindan Kenkyukai Shi, 28 (2):85-89.
66. Tashiro M, Fushimi K, Kawano K, et al (2017). Comparison of Efficacy of Antimicrobial Agents Among Hospitalized Patients With Mycoplasma pneumoniae Pneumonia in Japan During Large Epidemics of Macrolide-Resistant M. pneumoniae Infections: A Nationwide Observational Study. Clin Infect Dis, 65 (11):1837-1842.
67. Du D, Liao S, Wu Y, et al (2017). Serological Analysis and Drug Resistance of Chlamydia pneumoniae and Mycoplasma pneumoniae in 4500 Healthy Subjects in Shenzhen, China. Biomed Res Int, 2017:3120138.
68. Tanaka T, Oishi T, Miyata I, et al (2017). Macrolide-Resistant Mycoplasma pneumoniae Infection, Japan, 2008-2015. Emerg Infect Dis, 23 (10):1703-1706.
69. Lee JK, Choi YY, Sohn YJ, et al (2022). Persistent high macrolide resistance rate and increase of macrolide-resistant ST14 strains among Mycoplasma pneumoniae in South Korea, 2019–2020. J Microbiol Immunol Infect, 55 (5):910-916.
70. Jiang T, Sun L, Wang T, et al (2023). The clinical significance of macrolide resistance in pediatric Mycoplasma pneumoniae infection during COVID-19 pandemic. Front Cell Infect Microbiol, 13:1181402.
71. Yen MH, Yan DC, Wang CJ, et al (2023). The clinical significance of and the factors associated with macrolide resistance and poor macrolide response in pediatric Mycoplasma pneumoniae infection: A retrospective study. J Microbiol Immunol Infect, 56 (3):634-640.
72. Zhan XW, Deng LP, Wang ZY, et al (2022). Correlation between Mycoplasma pneumoniae drug resistance and clinical characteristics in bronchoalveolar lavage fluid of children with refractory Mycoplasma pneumoniae pneumonia. Ital J Pediatr, 48 (1):190.
73. Li J, Maiwald M, Loo LH, et al (2022). Clinical characteristics of macrolide-resistant Mycoplasma pneumoniae infections among hospitalised children in Singapore. Ann Acad Med Singap, 51 (10):653-656.
2. Shin EJ, Kim Y, Jeong JY, et al (2018). The changes of prevalence and etiology of pediatric pneumonia from National Emergency Department Information System in Korea, between 2007 and 2014. Korean J Pediatr, 61 (9):291-300.
3. Waites KB, Talkington DF (2004). Mycoplasma pneumoniae and its role as a human pathogen. Clin Microbiol Rev, 17 (4):697-728.
4. Narita M (2010). Pathogenesis of extrapulmonary manifestations of Mycoplasma pneumoniae infection with special reference to pneumonia. J Infect Chemother, 16 (3):162-9.
5. Principi N, Esposito S (2013). Macrolide-resistant Mycoplasma pneumoniae: its role in respiratory infection. J Antimicrob Chemother, 68 (3):506-11.
6. de Groot RCA, Meyer Sauteur PM, Unger WWJ, et al (2017). Things that could be Mycoplasma pneumoniae. J Infect, 74 Suppl 1:S95-S100.
7. Pereyre S, Goret J, Bébéar C (2016). Mycoplasma pneumoniae: Current Knowledge on Macrolide Resistance and Treatment. Front Microbiol, 7:974.
8. Dumke R, Catrein I, Herrmann R, Jacobs E (2004). Preference, adaptation and survival of Mycoplasma pneumoniae subtypes in an animal model. Int J Med Microbiol, 294 (2-3):149-55.
9. Atkinson TP, Balish MF, Waites KB (2008). Epidemiology, clinical manifestations, pathogenesis and laboratory detection of Mycoplasma pneumoniae infections. FEMS Microbiol Rev, 32 (6):956-73.
10. Rasmussen JN, Voldstedlund M, Andersen RL, et al (2010). Increased incidence of Mycoplasma pneumoniae infections detected by laboratory-based surveillance in Denmark in 2010. Euro Surveill, 15 (45): 19708.
11. Gullsby K, Olsen B, Bondeson K (2019). Molecular Typing of Mycoplasma pneumoniae Strains in Sweden from 1996 to 2017 and the Emergence of a New P1 Cytadhesin Gene, Variant 2e. J Clin Microbiol, 57 (6):e00049-19.
12. Morozumi M, Takahashi T, Ubukata K (2010). Macrolide-resistant Mycoplasma pneumoniae: characteristics of isolates and clinical aspects of community-acquired pneumonia. J Infect Chemother, 16 (2):78-86.
13. Chironna M, Sallustio A, Esposito S, et al (2011). Emergence of macrolide-resistant strains during an outbreak of Mycoplasma pneumoniae infections in children. J Antimicrob Chemother, 66 (4):734-737.
14. Okazaki N, Narita M, Yamada S, et al (2001). Characteristics of macrolide-resistant Mycoplasma pneumoniae strains isolated from patients and induced with erythromycin in vitro. Microbiol Immunol, 45 (8):617-20.
15. Hubert D, Dumke R, Weichert S, et al (2021). Emergence of Macrolide-Resistant Mycoplasma pneumoniae during an Outbreak in a Primary School: Clinical Characterization of Hospitalized Children. Pathogens, 10 (3):328.
16. Miyashita N, Akaike H, Teranishi H, et al (2013). Macrolide-Resistant Mycoplasma pneumoniae Pneumonia in Adolescents and Adults: Clinical Findings, Drug Susceptibility, and Therapeutic Efficacy. Antimicrob Agents Chemother, 57 (10):5181-5185.
17. Moher D, Liberati A, Tetzlaff J, et al (2009). Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med, 151 (4):264-9, W64.
18. Wang Y, Xu B, Wu X, et al (2021). Increased Macrolide Resistance Rate of M3562 Mycoplasma pneumoniae Correlated With Macrolide Usage and Genotype Shifting. Front Cell Infect Microbiol, 11:675466.
19. Sun H, Xue G, Yan C, et al (2017). Changes in Molecular Characteristics of Mycoplasma pneumoniae in Clinical Specimens from Children in Beijing between 2003 and 2015. PLoS One, 12 (1):e0170253.
20. Yan C, Xue G, Zhao H, et al (2019). Molecular and clinical characteristics of severe Mycoplasma pneumoniae pneumonia in children. Pediatr Pulmonol, 54 (7):1012-1021.
21. Nakamura Y, Oishi T, Kaneko K, et al (2021). Recent acute reduction in macrolide-resistant Mycoplasma pneumoniae infections among Japanese children. J Infect Chemother, 27 (2):271-276.
22. Okada T, Morozumi M, Tajima T, et al (2012). Rapid effectiveness of minocycline or doxycycline against macrolide-resistant Mycoplasma pneumoniae infection in a 2011 outbreak among Japanese children. Clin Infect Dis, 55 (12):1642-9.
23. Morozumi M, Tajima T, Sakuma M, et al (2020). Sequence Type Changes Associated with Decreasing Macrolide-Resistant Mycoplasma pneumoniae, Japan. Emerg Infect Dis, 26 (9):2210-2213.
24. Xue G, Li M, Wang N, et al (2018). Comparison of the molecular characteristics of Mycoplasma pneumoniae from children across different regions of China. PLoS One, 13 (8):e0198557.
25. Zhao F, Li J, Liu J, et al (2019). Antimicrobial susceptibility and molecular characteristics of Mycoplasma pneumoniae isolates across different regions of China. Antimicrob Resist Infect Control, 8:143.
26. Lenglet A, Herrador Z, Magiorakos AP, et al (2012). Surveillance status and recent data for Mycoplasma pneumoniae infections in the European Union and European Economic Area, January 2012. Euro Surveill, 17 (5): 20075.
27. Adriaenssens N, Coenen S, Versporten A, et al (2011). European Surveillance of Antimicrobial Consumption (ESAC): outpatient macrolide, lincosamide and streptogramin (MLS) use in Europe (1997-2009). J Antimicrob Chemother, 66 Suppl 6:vi37-45.
28. Dumke R, Ziegler T (2019). Long-Term Low Rate of Macrolide-Resistant Mycoplasma pneumoniae Strains in Germany. Antimicrob Agents Chemother, 63 (5):e00455-19.
29. Ferguson GD, Gadsby NJ, Henderson SS, et al (2013). Clinical outcomes and macrolide resistance in Mycoplasma pneumoniae infection in Scotland, UK. J Med Microbiol, 62 (Pt 12):1876-1882.
30. Kurkela S, Puolakkainen M, Hokynar K, et al (2019). Mycoplasma pneumoniae outbreak, Southeastern Finland, 2017–2018: molecular epidemiology and laboratory diagnostic lessons. Eur J Clin Microbiol Infect Dis, 38 (10):1867-1871.71.
31. Pereyre S, Guyot C, Renaudin H, et al (2004). In vitro selection and characterization of resistance to macrolides and related antibiotics in Mycoplasma pneumoniae. Antimicrob Agents Chemother, 48 (2):460-5.
32. Waites KB, Balish MF, Atkinson TP (2008). New insights into the pathogenesis and detection of Mycoplasma pneumoniae infections. Future Microbiol, 3 (6):635-48.
33. Morozumi M, Hasegawa K, Kobayashi R, et al (2005). Emergence of macrolide-resistant Mycoplasma pneumoniae with a 23S rRNA gene mutation. Antimicrob Agents Chemother, 49 (6):2302-6.
34. Cao B, Zhao CJ, Yin YD, et al (2010). High prevalence of macrolide resistance in Mycoplasma pneumoniae isolates from adult and adolescent patients with respiratory tract infection in China. Clin Infect Dis, 51 (2):189-94.
35. Zhao F, Liu G, Wu J, et al (2013). Surveillance of Macrolide-Resistant Mycoplasma pneumoniae in Beijing, China, from 2008 to 2012. Antimicrob Agents Chemother, 57 (3):1521-1523.
36. Zhao F, Liu L, Tao X, et al (2015). Culture-Independent Detection and Genotyping of Mycoplasma pneumoniae in Clinical Specimens from Beijing, China. PLoS One, 10 (10):e0141702.
37. Zhao H, Li S, Cao L, et al (2014). Surveillance of Mycoplasma pneumoniae infection among children in Beijing from 2007 to 2012. Chin Med J (Engl), 127 (7):1244-8.
38. Zhou Y, Zhang Y, Sheng Y, et al (2014). More Complications Occur in Macrolide-Resistant than in Macrolide-Sensitive Mycoplasma pneumoniae Pneumonia. Antimicrob Agents Chemother, 58 (2):1034-1038.
39. Oishi T, Takahashi K, Wakabayashi S, et al (2019). Comparing Antimicrobial Susceptibilities among Mycoplasma pneumoniae Isolates from Pediatric Patients in Japan between Two Recent Epidemic Periods. Antimicrob Agents Chemother, 63 (7):e02517-18.
40. Yu JL, Song QF, Xie ZW, et al (2017). iTRAQ-based Quantitative Proteomics Study in Patients with Refractory Mycoplasma pneumoniae Pneumonia. Jpn J Infect Dis, 70 (5):571-578.
41. Cardinale F, Chironna M, Chinellato I, et al (2013). Clinical Relevance of Mycoplasma pneumoniae Macrolide Resistance in Children. J Clin Microbiol, 51 (2):723-724.
42. Spuesens EB, Meyer Sauteur PM, Vink C, et al (2014). Mycoplasma pneumoniae infections--does treatment help? J Infect, 69 Suppl 1:S42-6.
43. Luo Z, Luo J, Liu E, et al (2014). Effects of prednisolone on refractory mycoplasma pneumoniae pneumonia in children. Pediatr Pulmonol, 49 (4):377-80.
44. Oliva A, Siccardi G, Migliarini A, et al (2020). Co-infection of SARS-CoV-2 with Chlamydia or Mycoplasma pneumoniae: a case series and review of the literature. Infection, 48 (6):871-877.
45. Rothstein TE, Cunningham SA, Rieke RA, et al (2022). Macrolide Resistance in Mycoplasma pneumoniae, Midwestern United States, 2014 to 2021. Antimicrob Agents Chemother, 66 (4):e0243221.
46. Guo Z, Liu L, Gong J, et al (2022). Molecular features and antimicrobial susceptibility of Mycoplasma pneumoniae isolates from paediatric inpatients in Weihai, China: Characteristics of M. pneumoniae In Weihai. J Glob Antimicrob Resist, 28:180-184.
47. Chen D, Zhang NL, Zhang T, et al (2021). [Detection of drug-resistance genes of Mycoplasma pneumoniae in bronchoalveolar lavage fluid of children with refractory Mycoplasma pneumoniae pneumonia]. Zhongguo Dang Dai Er Ke Za Zhi, 23(7):707-712.
48. Kakiuchi T, Miyata I, Kimura R, et al (2021). Clinical Evaluation of a Novel Point-of-Care Assay To Detect Mycoplasma pneumoniae and Associated Macrolide-Resistant Mutations. J Clin Microbiol, 59 (7):e0324520.
49. Kuo CY, Tsai WC, Lee HF, et al (2022). The epidemiology, clinical characteristics, and macrolide susceptibility of Mycoplasma pneumoniae pneumonia in children in Southern Taiwan, 2019-2020. J Microbiol Immunol Infect, 55(4):611-619.
50. Dou HW, Tian XJ, Xin L, et al (2020). Mycoplasma pneumoniae Macrolide Resistance and MLVA Typing in Children in Beijing, China, in 2016: Is It Relevant? Biomed Environ Sci, 33 (12):916-924.
51. Morinaga Y, Suzuki H, Notake S, et al (2020). Evaluation of GENECUBE Mycoplasma for the detection of macrolide-resistant Mycoplasma pneumoniae. J Med Microbiol, 69 (12):1346-1350.
52. Rivaya B, Jordana-Lluch E, Fernández-Rivas G, et al (2020). Macrolide resistance and molecular typing of Mycoplasma pneumoniae infections during a 4 year period in Spain. J Antimicrob Chemother, 75 (10):2752-2759.
53. Hung HM, Chuang CH, Chen YY, et al (2021). Clonal spread of macrolide-resistant Mycoplasma pneumoniae sequence type-3 and type-17 with recombination on non-P1 adhesin among children in Taiwan. Clin Microbiol Infect, 27 (8):1169.e1-1169.e6.
54. Noori Goodarzi N, Pourmand MR, Arfaatabar M, et al (2020). First Detection and Characterization of Macrolide-Resistant Mycoplasma pneumoniae from People with Community-Acquired Pneumonia in Iran. Microb Drug Resist, 26 (3):245-250.
55. Waites KB, Ratliff A, Crabb DM, et al (2019). Macrolide-Resistant Mycoplasma pneumoniae in the United States as Determined from a National Surveillance Program. J Clin Microbiol, 57 (11): e00968-19.
56. Guo D, Hu W, Xu B, et al (2019). Allele-specific real-time PCR testing for minor macrolide-resistant Mycoplasma Pneumoniae. BMC Infect Dis, 19 (1):616.
57. Yang TI, Chang TH, Lu CY, et al (2019). Mycoplasma pneumoniae in pediatric patients: Do macrolide-resistance and/or delayed treatment matter? J Microbiol Immunol Infect, 52 (2):329-335.
58. Lu CY, Yen TY, Chang LY, et al (2020). Multiple-locus variable-number tandem-repeat analysis (MLVA) of macrolide-susceptible and -resistant Mycoplasma pneumoniae in children in Taiwan. J Formos Med Assoc, 119 (10):1539-1545.
59. Rodriguez N, Mondeja B, Sardiñas R, et al (2019). First detection and characterization of macrolide-resistant Mycoplasma pneumoniae strains in Cuba. Int J Infect Dis, 80:115-117.
60. Zhao F, Liu J, Shi W, et al (2019). Antimicrobial susceptibility and genotyping of Mycoplasma pneumoniae isolates in Beijing, China, from 2014 to 2016. Antimicrob Resist Infect Control, 8:18.
61. Loconsole D, De Robertis AL, Mallamaci R, et al (2019). First Description of Macrolide-Resistant Mycoplasma pneumoniae in Adults with Community-Acquired Pneumonia in Italy. Biomed Res Int, 2019:7168949.
62. Katsukawa C, Kenri T, Shibayama K, et al (2019). Genetic characterization of Mycoplasma pneumoniae isolated in Osaka between 2011 and 2017: Decreased detection rate of macrolide-resistance and increase of p1 gene type 2 lineage strains. PLoS One, 14 (1):e0209938.
63. Guo DX, Hu WJ, Wei R, et al (2019). Epidemiology and mechanism of drug resistance of Mycoplasma pneumoniae in Beijing, China: A multicenter study. Bosn J Basic Med Sci, 19 (3):288-296.
64. Choi JH, Seong GM, Ko Y, et al (2019). Prevalence and Clinical Features of Community-Acquired Pneumonia Caused by Macrolide-Resistant Mycoplasma pneumoniae Isolated from Adults in Jeju Island. Microb Drug Resist, 25 (4):577-581.
65. Shinto K, Kato K, Narita T, et al (2018). [Evaluation of novel nucleic acid detection kit for Mycoplasma pneumoniae]. Rinsho Biseibutshu Jinsoku Shindan Kenkyukai Shi, 28 (2):85-89.
66. Tashiro M, Fushimi K, Kawano K, et al (2017). Comparison of Efficacy of Antimicrobial Agents Among Hospitalized Patients With Mycoplasma pneumoniae Pneumonia in Japan During Large Epidemics of Macrolide-Resistant M. pneumoniae Infections: A Nationwide Observational Study. Clin Infect Dis, 65 (11):1837-1842.
67. Du D, Liao S, Wu Y, et al (2017). Serological Analysis and Drug Resistance of Chlamydia pneumoniae and Mycoplasma pneumoniae in 4500 Healthy Subjects in Shenzhen, China. Biomed Res Int, 2017:3120138.
68. Tanaka T, Oishi T, Miyata I, et al (2017). Macrolide-Resistant Mycoplasma pneumoniae Infection, Japan, 2008-2015. Emerg Infect Dis, 23 (10):1703-1706.
69. Lee JK, Choi YY, Sohn YJ, et al (2022). Persistent high macrolide resistance rate and increase of macrolide-resistant ST14 strains among Mycoplasma pneumoniae in South Korea, 2019–2020. J Microbiol Immunol Infect, 55 (5):910-916.
70. Jiang T, Sun L, Wang T, et al (2023). The clinical significance of macrolide resistance in pediatric Mycoplasma pneumoniae infection during COVID-19 pandemic. Front Cell Infect Microbiol, 13:1181402.
71. Yen MH, Yan DC, Wang CJ, et al (2023). The clinical significance of and the factors associated with macrolide resistance and poor macrolide response in pediatric Mycoplasma pneumoniae infection: A retrospective study. J Microbiol Immunol Infect, 56 (3):634-640.
72. Zhan XW, Deng LP, Wang ZY, et al (2022). Correlation between Mycoplasma pneumoniae drug resistance and clinical characteristics in bronchoalveolar lavage fluid of children with refractory Mycoplasma pneumoniae pneumonia. Ital J Pediatr, 48 (1):190.
73. Li J, Maiwald M, Loo LH, et al (2022). Clinical characteristics of macrolide-resistant Mycoplasma pneumoniae infections among hospitalised children in Singapore. Ann Acad Med Singap, 51 (10):653-656.
| Files | ||
| Issue | Vol 54 No 3 (2025) | |
| Section | Review Article(s) | |
| Keywords | ||
| Macrolide-resistant Mycoplasma pneumoniae Meta-analysis Antimicrobial resistance Drug resistance | ||
| Rights and permissions | |
|
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
How to Cite
1.
Alavi Darazam I, Rabiei MM, Javandoust Gharehbagh F, Hatami F, Shahrokhi S, Akhgarzad A, Allahverdi Nazhand H, Ebadi H, Zeininasab AH, Kazeminia N, Lotfollahi L, Shojaee S. Recent Macrolide Resistance Pattern of Mycoplasma Pneumonia in the World: A Systematic Review and Meta-Analysis. Iran J Public Health. 2025;54(3):530-541.
